PEMF for
Chronic Pain:

June 2026 · 11 min read · Clinical Education

What Is Chronic Pain?

Chronic pain is pain lasting more than 3 months — a threshold where pain transitions from a symptom signaling tissue damage into an independent disease in its own right. The critical distinction: acute pain warns of injury and resolves as healing occurs. Chronic pain has become self-sustaining, driven by changes in the nervous system that persist even after the original injury has resolved.

Globally, chronic pain affects 30–40% of adults. In the Philippines, conservative estimates place the burden at 36 million patients — a population larger than the combined chronic pain populations of Australia and New Zealand. These patients consume a disproportionate share of healthcare resources, generate significant productivity losses, and represent the largest underserved segment in Philippine clinical medicine.

Why Chronic Pain Persists: The Neurobiology of Chronification

Chronic pain is not simply acute pain that hasn't healed — it is a fundamentally different biological state driven by neuroplastic changes across multiple levels of the pain-processing system:

1. Peripheral sensitization: Injured or inflamed tissues sensitize primary nociceptive neurons (C-fibers, A-δ fibers). The activation threshold drops — stimuli that previously caused no pain now trigger continuous signaling. Inflammatory mediators (bradykinin, prostaglandins, substance P) maintain this sensitized state.
2. Central sensitization: Sustained nociceptive input into the dorsal horn induces wind-up — a progressive amplification of spinal cord responses. AMPA and NMDA glutamate receptors are upregulated; inhibitory interneurons are suppressed. The spinal cord is now amplifying rather than gating pain signals.
3. Descending facilitation failure: Healthy pain modulation depends on descending inhibitory pathways from the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM), releasing serotonin and norepinephrine to suppress spinal nociception. In chronic pain, this system shifts toward net facilitation — the brain actively amplifies pain rather than suppressing it.
4. Neuroinflammation: Microglial activation in the spinal cord dorsal horn releases pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) that further sensitize neurons and sustain the pain state. This neuroinflammatory loop is largely inaccessible to conventional analgesics.
5. Structural brain changes: Sustained chronic pain reduces gray matter volume in the prefrontal cortex, anterior cingulate cortex, and thalamus — regions critical for cognitive modulation of pain. These structural changes correlate with catastrophizing, anxiety, and comorbid sleep disruption, all of which amplify perceived pain intensity.

The implication for treatment is fundamental: targeting the peripheral injury alone will not resolve chronic pain once these central changes are established. Effective treatment must work at the level of the sensitized nervous system itself.

Why Conventional Treatments Fall Short

Standard chronic pain management — NSAIDs, opioids, physiotherapy, and corticosteroid injections — was designed for acute pain physiology. It addresses tissue inflammation and peripheral nociception but does not reverse central sensitization, restore descending inhibitory control, or resolve neuroinflammation.

• NSAIDs/COX-2 inhibitors: Reduce peripheral prostaglandin synthesis but have no effect on spinal dorsal horn sensitization or microglial activation. Long-term use carries GI, cardiovascular, and renal risk with diminishing efficacy.
• Opioids: Short-term analgesic effect, but opioid-induced hyperalgesia (OIH) paradoxically increases pain sensitivity with prolonged use. Addiction risk is a major concern in the Philippine clinical context.
• Corticosteroid injections: Local anti-inflammatory effect for acute flares; repeated injections accelerate cartilage degradation and do not address central sensitization.
• Conventional physiotherapy: Valuable for structural restoration, but the 2025 multicenter RCT (PMC11914662, n=91) found standard care alone achieved only 10% pain reduction vs. 36% in the PEMF group — confirming that conventional approaches are insufficient for moderate-to-severe chronic pain.

How PEMF Interrupts the Chronic Pain Cycle

PEMF (Pulsed Electromagnetic Field therapy) works on chronic pain through 5 distinct mechanisms that directly address the neurobiological drivers of pain chronification:

• Membrane stabilization: Pulsed electromagnetic fields restore normal resting membrane potential in sensitized nociceptive neurons, raising the action potential threshold. Spontaneous firing — the hallmark of central sensitization — is suppressed. Effect initiates within the first 1–3 sessions.
• Adenosine-A2A receptor activation: PEMF selectively activates adenosine-A2A receptors in the spinal dorsal horn, triggering inhibitory cascades that suppress glutamate (AMPA/NMDA) and substance P release. This is a direct anti-wind-up mechanism with no pharmacological equivalent.
• Microcirculation restoration: Electromagnetic fields improve periarticular and perineural blood flow, clearing inflammatory metabolites (lactate, bradykinin, prostaglandins) that sustain peripheral sensitization. Tissue oxygen delivery improves and edema resolves.
• Cytokine modulation: PEMF suppresses pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6) at both peripheral tissue and central (spinal cord microglial) levels. This addresses the neuroinflammatory component of chronic pain directly — something no oral anti-inflammatory achieves at the spinal level.
• ATP synthesis upregulation: Chronic pain states are associated with mitochondrial dysfunction and cellular energy deficit in affected tissues. PEMF upregulates ATP synthesis via increased cytochrome c oxidase activity, restoring normal cellular function and reducing the metabolic stress that perpetuates nociceptive sensitization.

PEMF Evidence Across Chronic Pain Conditions

When to Start PEMF: The Window of Intervention

One of the most clinically important findings in chronic pain neurobiology is that intervention timing significantly affects outcomes. Central sensitization is reversible in its early phases but becomes increasingly entrenched as the pain state is maintained. Two key intervention windows exist:

• Sub-acute phase (1–3 months): Peripheral sensitization is dominant; central changes are initiating but not yet established. PEMF at this stage can prevent chronification by resolving peripheral nociceptive drive before central wind-up becomes self-sustaining. This is the highest-ROI intervention point.
• Established chronic phase (>3 months): Central sensitization is established. PEMF remains effective — the 2025 RCT data (PMC11914662) is specifically in patients with established chronic back pain — but treatment courses are longer (10–20 sessions minimum) and combination protocols are preferred.

The clinical implication: PEMF should be considered as a first-line non-invasive intervention from the sub-acute phase onward, not a last resort after medications have failed.

The Chronic Pain PEMF Protocol

• Frequency range: 5–50 Hz depending on indication (low 5–10 Hz for neurological/fibromyalgia; 25–50 Hz for musculoskeletal/inflammatory)
• Intensity: 5–30 mT for musculoskeletal; 0.5–5 mT for neurological indications
• Session duration: 30–40 minutes
• Frequency: 2–3 sessions per week in acute phase; 1–2 sessions per week for maintenance
• Course length: 10–12 sessions initial; reassess at 6 sessions using VAS/NRS
• Combination protocol: PEMF before manual therapy or exercise therapy for synergistic effect (tissue prepared, thresholds lowered)
• Expected timeline: Meaningful improvement in VAS typically observed at sessions 3–6; full course effect at 8–12 weeks

Patient Selection: Who Benefits Most

PEMF is broadly applicable across chronic pain populations. The following patient profiles show the strongest outcomes:

• Treatment-refractory patients: Those who have not responded adequately to NSAIDs, physiotherapy, or injections — the PEMF mechanism is non-overlapping with pharmacological approaches
• Polypharmacy patients: Chronic pain patients on multiple medications benefit from 55% reduction in medication consumption (PMC11914662), reducing drug interactions and side effects
• Patients with comorbid anxiety/sleep disruption: The same PEMF mechanism (cortisol suppression, membrane stabilization) addresses anxiety and sleep simultaneously — 40% HAMA reduction and PSQI improvement documented alongside pain relief
• Elderly patients with contraindications to surgery or strong analgesics: PEMF's safety profile (no systemic effects, no organ toxicity) is uniquely valuable in this population
• Physically active patients (athletes, BPO workers, commuters): High-demand patients who cannot afford treatment downtime benefit from PEMF's non-invasive, no-recovery protocol

The Philippine Chronic Pain Market

The Philippines presents a chronic pain treatment gap that is, by Southeast Asian standards, exceptional. Conservative estimates from Philippine Health Insurance Corporation (PhilHealth) data suggest 30–35% of adult Filipinos experience chronic pain — approximately 24–30 million patients at any given time, scaling to 36 million when adjusting for underdiagnosis.

Three demographic segments are particularly significant for clinic investors:

• BPO/office workforce (1.5M+ workers): Sedentary posture, high screen time, and shift-work sleep disruption create a population with elevated chronic cervical, lumbar, and myofascial pain — able to pay, seeking private clinic care, and underserved by public health infrastructure
• Diabetic patients (9M diagnosed): Peripheral neuropathy (30–50% incidence) and wound healing complications create a large, high-need chronic pain population with documented PEMF responsiveness
• Aging population: The Philippines' 60+ population is projected to reach 12 million by 2030; osteoarthritis, spinal stenosis, and post-fracture chronic pain will create sustained demand for non-pharmacological pain management

70+ Israeli clinics (population: 9M) are already operating this model — now expanding to the Philippines.

Contraindications

PEMF is broadly safe. Absolute contraindications are narrow: active implanted pacemaker or neurostimulator, pregnancy (precautionary), active epilepsy (neurostimulatory frequencies), and active malignancy in the treatment area. PEMF is safe in elderly patients, patients with joint replacements (titanium implants are non-magnetic), and patients on anticoagulants.

Frequently Asked Questions

How is chronic pain PEMF different from acute pain PEMF?

Protocol parameters differ: chronic pain typically requires longer treatment courses (10–20 sessions vs. 6–10 for acute), lower-frequency settings for neurological indications (5–15 Hz vs. 25–50 Hz), and greater emphasis on combination with manual therapy to address both central and peripheral components. The mechanism is the same; the dosing is adapted to the chronified neural state.

Can PEMF be combined with medications a patient is already taking?

Yes. PEMF has no pharmacokinetic interactions with NSAIDs, anticonvulsants, antidepressants, or opioids. The 2025 multicenter RCT (PMC11914662) included patients on standard pain medication; the PEMF group still achieved 55% medication reduction over the course of treatment, suggesting PEMF enables progressive medication tapering rather than conflicting with existing regimens.

What is the typical response rate?

Across the major RCTs, 65–80% of chronic pain patients report clinically meaningful improvement (≥30% pain reduction) after a full 10–12 session PEMF course. Non-responders typically have severe central sensitization or significant psychological comorbidity that requires additional psychological support alongside PEMF. There are no serious adverse events in any large-scale PEMF trial to date.